Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. (BHVN) reported that the FDA's Division of Neurology 1 extended the PDUFA review for the troriluzole NDA by three months in May 2025 to allow a full review of recent submissions. At that time the Division had planned an advisory committee meeting to discuss the application.
On August 21, 2025 the Division informed the company that an advisory committee meeting is no longer needed for regulatory decision making. The FDA's decision on the NDA is expected during the fourth quarter of 2025. The report and Exhibit 99.1 are being furnished and are not "filed" for Section 18 purposes.
Biohaven Ltd. filed a prospectus supplement covering the resale by a selling shareholder of 3,588,688 common shares that were issued as share consideration under an amended acquisition agreement.
The amendment to the Knopp Biosciences purchase arrangement replaces a scaled high single digit to low teens royalty with a flat mid-single digit royalty on BHV-7000 and related pipeline programs. It also removes up to $562.5 million in commercial sales-based milestones and reduces developmental and regulatory milestones from up to $575 million to up to $210 million tied to BHV-7000 approvals across multiple regions, plus up to $60 million tied to U.S. approval of other Kv7 programs. Biohaven can choose to pay these contingent milestones in cash or in its common shares.
Biohaven Ltd. (BHVN) prospectus supplement describes registered resale of 3,588,688 common shares issued to a selling shareholder under the May 1, 2024 Amendment to the Membership Interest Purchase Agreement (the "Knopp Amendment"). The Knopp Amendment replaces a scaled high-single-digit/low-teens royalty with a flat mid-single-digit royalty for BHV-7000 and pipeline programs, removes up to $562.5 million in commercial sales-based milestones and reduces development/regulatory milestones from up to $575 million to up to $210 million for BHV-7000 (with $25 million already paid) plus up to $60 million for other Kv7 programs in the U.S.; Biohaven may pay these contingent milestones in cash or common shares.
The filing summarizes corporate charter terms under BVI law, authorized share limits (200,000,000 common; 10,000,000 preferred), and reports 105,790,997 common shares issued and outstanding as of August 14, 2025. It also discloses governance provisions that may allow the Board to issue preferred shares without shareholder approval and other anti-takeover features.
Janus Henderson Group plc reports beneficial ownership of 5,053,528 shares of Biohaven Ltd. common stock, representing approximately 4.9% of the class. The position is disclosed as shared voting and shared dispositive power held through Janus Henderson subsidiaries that act as registered investment advisers to managed portfolios.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Biohaven, and it includes a power of attorney delegating authority to named compliance officers to execute required ownership filings.
Biohaven Ltd. reported a continued operating loss and a material financing transaction that altered its balance sheet. Total assets were $550.4 million versus $615.1 million at year-end, with $165.8 million in cash and cash equivalents and $239.2 million in marketable securities. The company recorded a net loss of $198.1 million for the quarter and $419.8 million for the six months, with basic and diluted loss per share of $1.94 and $4.11, respectively.
Biohaven completed a $250.0 million secured notes financing under a Note Purchase Agreement and elected fair-value accounting for those notes, which increased non-current notes payable to $257.1 million and raised total liabilities to $415.8 million. Research and development expense declined versus the prior-year periods, reducing operating expense and operating loss, but operating cash use remained substantial at $333.1 million for the six months. The company also reported significant contingent milestone and commercial payment obligations under license and acquisition agreements totaling up to $3.185 billion, which are not recognized as liabilities because the triggering events were not considered probable.
Biohaven Ltd. furnished a Current Report on Form 8-K to announce a press release reporting its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the cover page of the report is provided in Inline XBRL as Exhibit 104.
The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference in other filings except by specific reference. The registrant is organized in the British Virgin Islands, its common shares trade under BHVN on the New York Stock Exchange, and the report is signed by Chief Financial Officer Matthew Buten.